Monoclonal antibodies against Plasmodium vivax Apical Membrane Antigen-1; revealing the mechanism of action of AMA1 and Investigating the association between Plasmodium vivax crt-o polymorphisms and chloroquine treatment failure in clinical cohort form Malaysia

July 28, 2023

“Monoclonal antibodies against Plasmodium vivax Apical Membrane Antigen-1; revealing the mechanism of action of AMA1” with Dr Lee Yeoh

We have recently developed monoclonal antibodies specific to Plasmodium vivax AMA1. These have shown extremely high reactivity to AMA1 via functional and inhibition assays in vitro. These antibodies are promising therapeutics in themselves, but are also exceptionally useful for their capability in dissecting the mechanism of PvAMA1’s function. Recent data suggest that PvAMA1 potentially facilitates invasion via two independent interactions.

“Investigating the association between Plasmodium vivax crt-o polymorphisms and chloroquine treatment failure in clinical cohort form Malaysia” with Angela Rumaseb
Increasing reports of resistance to a frontline malaria blood-stage treatment, chloroquine (CQ), raise concerns for the elimination of Plasmodium vivax. The absence of an effective molecular marker of CQ resistance in P. vivax greatly constrains surveillance of this emerging threat. A recent genetic cross between CQ sensitive and CQ resistant (CQR) NIH-1993 strains of P. vivax linked a moderate CQR phenotype with two candidate markers in P. vivax CQ resistance transporter gene (pvcrt-o): MS334 and In9pvcrt. We investigated the association between the two candidate markers and treatment efficacy in CQR P. vivax clinical isolates from a low-endemic setting in Malaysia.

Webinars